Free Trial

Avalon GloboCare (ALBT) Competitors

Avalon GloboCare logo
$2.68 -0.02 (-0.74%)
As of 02:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALBT vs. JATT, IMA, PLUR, BCAB, MDCX, XFOR, MURA, RANI, DYAI, and MRSN

Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include JATT Acquisition (JATT), ImageneBio (IMA), Pluri (PLUR), BioAtla (BCAB), Medicus Pharma (MDCX), X4 Pharmaceuticals (XFOR), Mural Oncology (MURA), Rani Therapeutics (RANI), Dyadic International (DYAI), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry.

Avalon GloboCare vs. Its Competitors

JATT Acquisition (NYSE:JATT) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

JATT Acquisition has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
Avalon GloboCare -1,451.94%N/A -75.12%

In the previous week, Avalon GloboCare had 2 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Avalon GloboCare and 1 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.75 beat Avalon GloboCare's score of 0.66 indicating that JATT Acquisition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
JATT Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avalon GloboCare
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

JATT Acquisition has higher earnings, but lower revenue than Avalon GloboCare.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
Avalon GloboCare$1.33M7.74-$7.90M-$19.96-0.13

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

JATT Acquisition beats Avalon GloboCare on 5 of the 9 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALBT vs. The Competition

MetricAvalon GloboCareMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.29M$3.14B$5.75B$10.26B
Dividend YieldN/A2.36%5.88%4.63%
P/E Ratio-0.1321.3577.0126.57
Price / Sales7.74458.94528.65122.51
Price / CashN/A45.4037.2060.49
Price / Book-0.249.6813.966.34
Net Income-$7.90M-$53.02M$3.29B$270.99M
7 Day Performance7.20%1.58%1.38%2.67%
1 Month Performance17.54%5.20%5.13%7.23%
1 Year Performance-13.27%9.53%84.67%27.97%

Avalon GloboCare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALBT
Avalon GloboCare
1.1037 of 5 stars
$2.68
-0.7%
N/A-25.7%$10.29M$1.33M-0.135Short Interest ↑
JATT
JATT Acquisition
N/A$2.21
+0.5%
N/A-48.1%$38.12MN/A0.003High Trading Volume
IMA
ImageneBio
3.3181 of 5 stars
$9.36
+0.8%
$35.50
+279.3%
-58.7%$37.63M$9.16M-1.2270Positive News
PLUR
Pluri
2.72 of 5 stars
$4.77
+0.8%
$12.00
+151.8%
-5.0%$37.52M$330K-0.86150Gap Down
BCAB
BioAtla
1.1671 of 5 stars
$0.63
+3.6%
$5.00
+689.9%
-57.0%$37.17M$11M-0.5860Positive News
MDCX
Medicus Pharma
2.0371 of 5 stars
$2.05
-2.2%
$23.50
+1,049.1%
N/A$36.44MN/A-1.53N/AAnalyst Upgrade
XFOR
X4 Pharmaceuticals
4.6402 of 5 stars
$3.18
-6.2%
$34.17
+974.4%
-83.8%$36.28M$2.56M-0.2180News Coverage
Positive News
Short Interest ↓
MURA
Mural Oncology
2.5538 of 5 stars
$2.08
+0.2%
$12.00
+478.3%
-36.1%$35.94MN/A-0.24119
RANI
Rani Therapeutics
3.1966 of 5 stars
$0.50
-1.0%
$7.33
+1,381.5%
-78.1%$35.58M$1.03M-0.54110Positive News
DYAI
Dyadic International
2.669 of 5 stars
$0.98
+1.2%
$6.00
+514.1%
-19.4%$35.36M$3.42M-5.147News Coverage
Short Interest ↑
MRSN
Mersana Therapeutics
4.1366 of 5 stars
$7.02
-0.4%
$56.60
+706.8%
-85.4%$35.01M$40.50M-0.48150News Coverage

Related Companies and Tools


This page (NASDAQ:ALBT) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners